This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
ChemoCentryx 미래 성장
Future 기준 확인 5/6
주요 정보
69.1%
수익 성장률
91.9%
EPS 성장률
| Biotechs 수익 성장 | 25.6% |
| 매출 성장률 | 85.1% |
| 향후 자기자본 수익 률 | 6.6% |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | n/a |
최근 미래 성장 업데이트
Recent updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09ChemoCentryx: Revisiting The Investment Case
Jun 21ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06
ChemoCentryx: Good Post-Approval Performance, But Needs More Time
Mar 03ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week
Jan 21Checking In On ChemoCentryx
Dec 15Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
Sep 29ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Aug 24Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook
Aug 11ChemoCentryx: CRL Less Likely
Jul 25ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price
Jul 11ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
Jun 08ChemoCentryx: CRL Likely
May 09ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
May 07Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate
May 04When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?
Mar 03ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04
ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
Jan 14Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?
Dec 31Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)
Dec 23ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study
Dec 21Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?
Dec 13Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?
Nov 22ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2024 | 419 | 68 | -6 | 116 | 1 |
| 12/31/2023 | 190 | -55 | -25 | -12 | 2 |
| 12/31/2022 | 64 | -140 | -94 | -52 | 2 |
| 6/30/2022 | 37 | -133 | -59 | -53 | N/A |
| 3/31/2022 | 27 | -141 | -54 | -45 | N/A |
| 12/31/2021 | 32 | -132 | -95 | -76 | N/A |
| 9/30/2021 | 34 | -121 | -112 | -84 | N/A |
| 6/30/2021 | 22 | -123 | -102 | -75 | N/A |
| 3/31/2021 | 69 | -63 | -101 | -75 | N/A |
| 12/31/2020 | 65 | -55 | -97 | -81 | N/A |
| 9/30/2020 | 71 | -41 | -89 | -82 | N/A |
| 6/30/2020 | 76 | -30 | -85 | -83 | N/A |
| 3/31/2020 | 34 | -65 | -81 | -79 | N/A |
| 12/31/2019 | 36 | -55 | -71 | -70 | N/A |
| 9/30/2019 | 35 | -51 | -66 | -65 | N/A |
| 6/30/2019 | 34 | -49 | -66 | -66 | N/A |
| 3/31/2019 | 42 | -40 | -44 | -43 | N/A |
| 12/31/2018 | 43 | -38 | 16 | 16 | N/A |
| 9/30/2018 | 90 | 12 | 36 | 38 | N/A |
| 6/30/2018 | 90 | 17 | 41 | 42 | N/A |
| 3/31/2018 | 84 | 14 | 19 | 20 | N/A |
| 12/31/2017 | 82 | 18 | 4 | 5 | N/A |
| 9/30/2017 | 31 | -29 | -10 | -10 | N/A |
| 6/30/2017 | 26 | -30 | -5 | -5 | N/A |
| 3/31/2017 | 20 | -31 | 76 | 76 | N/A |
| 12/31/2016 | 12 | -40 | 39 | 39 | N/A |
| 9/30/2016 | 7 | -44 | 38 | 39 | N/A |
| 6/30/2016 | 3 | -48 | 38 | 38 | N/A |
| 3/31/2016 | N/A | -51 | N/A | -41 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: CCXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
수익 vs 시장: CCXI is forecast to become profitable over the next 3 years, which is considered above average market growth.
고성장 수익: CCXI is expected to become profitable in the next 3 years.
수익 대 시장: CCXI's revenue (85.1% per year) is forecast to grow faster than the US market (6.7% per year).
고성장 수익: CCXI's revenue (85.1% per year) is forecast to grow faster than 20% per year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: CCXI's Return on Equity is forecast to be low in 3 years time (6.6%).